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Summary
There has been increased interest in the prophylactic and therapeutic use of high-ﬂow nasal oxygen in
patients with, or at risk of, non-hypercapnic respiratory failure. There are no randomised trials examining
the efﬁcacy of high-ﬂow nasal oxygen in high-risk cardiac surgical patients. We sought to determine
whether routine administration of high-ﬂow nasal oxygen, compared with standard oxygen therapy, leads
to reduced hospital length of stay after cardiac surgery in patients with pre-existing respiratory disease at
high risk for postoperative pulmonary complications. Adult patients with pre-existing respiratory disease
undergoing elective cardiac surgery were randomly allocated to receive high-ﬂow nasal oxygen (n = 51) or
standard oxygen therapy (n = 49). The primary outcome was hospital length of stay and all analyses were
carried out on an intention-to-treat basis. Median (IQR [range]) hospital length of stay was 7 (6–9 [4–30])
days in the high-ﬂow nasal oxygen group and 9 (7–16 [4–120]) days in the standard oxygen group
(p=0.012). Geometric mean hospital length of stay was 29% lower in the high-ﬂow nasal group (95%CI
11–44%, p = 0.004). High-ﬂow nasal oxygen was also associated with fewer intensive care unit re-admis-
sions (1/49 vs. 7/45; p = 0.026). When compared with standard care, prophylactic postoperative high-ﬂow
nasal oxygen reduced hospital length of stay and intensive care unit re-admission. This is the ﬁrst
randomised controlled trial examining the effect of prophylactic high-ﬂow nasal oxygen use on patient-
centred outcomes in cardiac surgical patients at high risk for postoperative respiratory complications.
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Introduction
Patients undergoing cardiac surgery are at signiﬁcant risk
of postoperative pulmonary complications, and these
complications may increase morbidity and mortality and
lead to prolonged intensive care unit (ICU) and hospital
length of stay (LOS) [1]. The reported incidence of
postoperative pulmonary complications following cardiac
surgery ranges from 8% to 79% [2]. Postoperative
pulmonary complications manifest early as hypoxaemia,
later pneumonia, and in rare cases also as acute respiratory
distress syndrome [3]. The incidence of postoperative
pulmonary complications is increased in patients with
intrinsic respiratory disease, asthma, chronic obstructive
pulmonary disease (COPD) and heavy smokers [4]. These
patients often stay longer in the ICU after surgery due to
lower respiratory tract infections, impaired ventilation and
the need for prolonged ventilatory support. They are also
more likely to require re-admission to ICU for unplanned
continuous positive airways pressure (CPAP), non-invasive
or invasive mechanical ventilation. Therefore, hospital stay
is prolonged compared with low-risk patients after cardiac
surgery [5–7]. A contributing mechanism of postoperative
pulmonary complications is atelectasis, which has been
shown to affect up to 90% of patients undergoing cardiac
surgery. Atelectasis has been shown to be resistant to
simple techniques such as patient positioning and incentive
spirometry [8]. Lung recruitment manoeuvres and positive
airways pressure may reduce atelectasis development, but
this effect is lost after tracheal extubation [9].
Prophylactic nasal CPAP reduces postoperative
pulmonary complications after cardiac surgery [10].
However, CPAP is costly and requires more intensive
involvement by hospital staff. In many hospitals, its use
requires admission to at least a high dependency area or
even ICU, thus further increasing costs. Apart from the
expense and extra healthcare provision costs, common
potential side-effects from CPAP include mask discomfort,
skin abrasions, inability to communicate effectively,
inability to eat or drink while the device is in use, inability
to mobilise and irritation from device noise [11, 12].
High-ﬂow nasal oxygen therapy delivers warmed
humidiﬁed oxygen and low level, ﬂow-dependent positive
airways pressure, and may be better tolerated than
CPAP or non-invasive ventilation; moreover, high-ﬂow
nasal oxygen enhances washout of nasopharyngeal dead
space, thus improving oxygenation [13–16]. It has been
shown that high-ﬂow nasal oxygen is both safe and non-
inferior to conventional CPAP in providing prophylactic
support to very preterm neonates after extubation while
the incidence of nasal trauma was signiﬁcantly lower than
in the CPAP group [17]. No study has assessed the effect
of prophylactic use of high-ﬂow nasal oxygen on hospital
stay in adult cardiac surgical patients with signiﬁcant risk
factors for postoperative pulmonary complications. We
therefore, decided to study high-risk patients with pre-
existing lung disease (COPD, asthma, recent lower respi-
ratory tract infection), heavy smokers or morbidly obese
patients (body mass index (BMI) ≥ 35 kg.m2), who were
expected to stay longer in ICU and hospital due to
increased respiratory complications. We tested the
hypothesis that routine administration of high-ﬂow nasal
oxygen leads to reduced hospital length of stay after
cardiac surgery compared with standard oxygen therapy.
Methods
Following national research ethics service (East Midlands
Research Ethics Committee UK) and local Research and
Development approval, written informed consent was
obtained from all patients. Patients scheduled for elective
cardiac surgery (coronary artery bypass grafting (CABG),
valve surgery or both) were screened for eligibility.
Patients were included in the trial if they were aged
> 18 years, had one or more patient-related risk
factors for postoperative pulmonary complications
(COPD, asthma, lower respiratory tract infection in
preceding four weeks, BMI ≥ 35 kg.m2, current (within
last six weeks) heavy smokers (> 10 pack years)) and were
capable of performing a 6-minute walk test (6MWT). Only
patients with a formal COPD or asthma diagnosis
(as deﬁned by British Thoracic Society and National
Institute for Health and Care Excellence) on inhaled
therapy were enrolled [18, 19]. Lower respiratory tract
infection was deﬁned according to National Institute for
Health and Care Excellence as an acute illness, usually
with cough as the main symptom, and with at least one
other lower respiratory tract symptom (such as fever,
sputum production, breathlessness, wheeze or chest
discomfort/pain) and no alternative explanation [20].
According to the trial protocol, patients in whom
high-ﬂow nasal oxygen was contraindicated (presence of
a nasal septal defect), those who needed CPAP
pre-operatively or those who did not meet tracheal
extubation criteria by 10.00 the day after surgery (as they
did not follow the local protocolised peri-operative
care pathway), were not studied. Randomisation was
performed using a computer-generated assignment
sequence and a centralised online system before the
induction of anaesthesia while the patients were in the
operating theatre. Participating patients were randomly
allocated in a 1:1 ratio (block randomisation procedure
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with randomly selected block sizes keeping the investiga-
tors blinded to the size of each block) to either the high-
ﬂow nasal oxygen or standard oxygen therapy group.
A research nurse or clinical investigator not involved in
the clinical care of the patient obtained the treatment
allocation and informed the ICU nursing staff in order
that the allocated therapy was prepared. We were,
therefore, unable to blind patients or nursing staff in the
ICU. Surgical and nursing teams responsible for deciding
when patients were discharged (and therefore hospital
stay) and other aspects of their postoperative care on the
surgical ward were blinded as to group allocation.
Study participants underwent a 6MWT before the
operation, conducted in a standard manner according to
the guidelines of the American Thoracic Society [21].
Additionally, patients underwent pre-operative spirometry
testing. This was repeated three times, and average
values for forced expiratory volume in one second (FEV1)
and forced vital capacity (FVC), were calculated.
The anaesthetic technique and surgical procedure
were not affected by patients’ participation in this
study. Anaesthesia was induced with midazolam, fentanyl
and propofol, neuromuscular blockade achieved with
pancuronium and anaesthesia maintained with a continuous
infusion of propofol and/or inhalational anaesthetic agent
at the discretion of the attending anaesthetist. All patients’
lungs were ventilated using volume control ventilation
and the same intra-operative ventilatory settings, in
accordance with local practice: tidal volume 6–8 ml.kg1
predicted body weight; positive end-expiratory pressure
(PEEP) level of 5 cmH2O; cessation of mechanical ventilation
and zero PEEP during cardiopulmonary bypass.
At the end of surgery, patients were transferred to the
ICU where they received standard post-cardiac surgery
monitoring and treatment. Patients’ tracheas were extu-
bated once they were normothermic and not bleeding,
had established a regular respiratory pattern, had no sig-
niﬁcant residual neuromuscular blockade and did not com-
plain of anything other than mild pain. Postoperative pain
relief was provided by regular paracetamol and opioid
analgesia for all patients, unless they had a speciﬁc con-
traindication (e.g. known drug allergy).
Following tracheal extubation, patients received either
high-ﬂow nasal oxygen or standard oxygen therapy, that
is, low-ﬂow oxygen via nasal prongs or a soft facemask,
according to the randomisation performed before surgery.
The high-ﬂow nasal oxygen was set up and connected to
the patients by the ICU nurses who had been trained
before the start of the study. The fraction of inspired oxy-
gen (FIO2) delivered was titrated to that which resulted in
a pulse oximeter saturation of at least 95% (93% for those
at risk of hypercapnic respiratory failure, such as con-
ﬁrmed COPD patients and morbidly obese patients)
according to the British Thoracic Society guidelines for oxy-
gen use in adult patients [22]. The FIO2 was actively
reduced to the minimum level which achieved this goal.
Gas ﬂow for the high-ﬂow nasal oxygen was calculated
for each patient, based on their body characteristics and
comfort level. The standard starting ﬂow rate was
30 l.min1, and this was adjusted up or down between a
range of 20–50 l.min1 with the aim of achieving a respi-
ratory rate of less than 16 breaths per minute and patient
comfort. Patients randomised to receive standard oxygen
therapy were ﬁtted with nasal prongs or a soft facemask
and the oxygen ﬂow titrated to provide oximetry satura-
tions of at least 95% (93% for those at risk of hypercapnic
respiratory failure, such as conﬁrmed COPD patients and
morbidly obese patients). Both groups of patients had
oxygen therapy prescribed for the ﬁrst 24 h postopera-
tively and were transferred to surgical wards once they
fulﬁlled pre-speciﬁed physiological criteria. Oxygen ther-
apy was discontinued after 24 h unless there was evi-
dence of respiratory deterioration (dyspnoea, oxygen
saturation < 95% (or < 93% for COPD and morbidly
obese patients), respiratory rate > 20 breaths per min-
ute). Patients randomly allocated to receive high-ﬂow
nasal oxygen could have high-ﬂow nasal oxygen contin-
ued for more than 24 h (in the ICU or surgical ward) if it
was deemed necessary. Patients who continued to be in
respiratory distress (respiratory rate > 20 breaths per
minute, oxygen saturation < 95% (or < 93% for COPD
and morbidly obese patients)) were treated initially by
increasing the FIO2. Failing these measures, CPAP, non-
invasive ventilation or, if necessary, invasive mechanical
ventilation were considered, as is standard practice at
our institution. Participation in the study did not preclude
any measures which the clinical team caring for the
patient felt were necessary. As part of their standard
care, all patients were instructed on appropriate respira-
tory exercises postoperatively. On postoperative day 5
or 6, patients had both the 6MWT and spirometry test-
ing repeated. Removal of chest drains was decided
upon by the surgical team, who also decided when
patients would be discharged from the hospital. The
surgical team and the physiotherapists were unaware of
the study group allocations unless oxygen therapy was
continued after discharge from ICU.
The primary outcome of the study was hospital stay.
Pre-speciﬁed secondary outcomes were: ICU stay; ICU
re-admission rate; in-hospital mortality rate; pulmonary
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function tests (postoperative FEV1 and FVC); 6MWT
(pre- and postoperatively) and postoperative quality of
recovery assessed using the postoperative quality of
recovery scale (PQRS) questionnaire [23]. The PQRS was
completed on the day of admission (baseline) and before
discharge (approximately 1 week after surgery), and
again 1 month following surgery by telephone contact.
The PQRS data were reported as the proportion of
patients recovered at each time-point (baseline, ﬁrst post-
operative week, ﬁrst postoperative month). We focused on
non-physiological recovery domains (nociceptive, cognitive,
activities of daily living (ADL), emotive) and overall patient
satisfaction. The PQRS questionnaires were conducted
face-to-face during hospital stay, and by telephone after
hospital discharge. Detailed information around how to
use the test and how different domains are being assessed
is provided on the PQRS website (http://www.postopqrs.
com/).
When planning our study, we analysed our hospital
database for more than 2000 cardiac surgical procedures
carried out in the year 2014, and found that mean (SD)
hospital stay was 10 (3) days in patients with the same
risk factors. We expected high-ﬂow nasal oxygen to
reduce mean length of stay by 2 days (a 20% relative
reduction) to 8 days; data from our trial in thoracic
surgery patients showed a 35% reduction in length of
stay, so we proposed that 20% was both feasible and
clinically signiﬁcant. Sample size calculation demon-
strated that 92 patients (46 per group) would provide
90% power to detect a mean difference of 2 days in
hospital length of stay. The required sample size was
increased to 100 patients (50 per group) to allow for a
5% loss to follow-up and drop-outs. Baseline data were
described using frequencies and percentages for catego-
rical variables and either mean and SD or median, IQR
and range for continuous variables. Total hospital stay
was calculated for all patients who were discharged alive.
As total hopsital length of stay was positively skewed,
comparisons between groups were made using the
Wilcoxon Rank Sum test and the ratio of geometric
means. A risk ratio (RR) was used to compare prolonged
stay (deﬁned as total hospital stay > 10 days) in the two
groups. Intensive care re-admission and death were
compared using Fisher’s exact test, and 6MWT and
pulmonary function tests were compared using linear
regression. Recovery proﬁles were compared using
Chi-squared tests and multi-level mixed-effect logistic
regression. All analyses were by intention-to-treat and
were performed using Stata version 15.1 (StataCorp.
2017. Stata Statistical Software: Release 15. College
Station, TX: StataCorp LLC) software and a p value < 0.05
was considered statistically signiﬁcant.
Results
One hundred patients were enrolled in the study,
51 patients were allocated to receive high-ﬂow nasal
oxygen and 49 to receive standard oxygen therapy. Of
these, six patients were not included in the ﬁnal analysis
due to protocol violation (two patients in each group
were not extubated by 10:00 on the morning after
surgery), surgery being cancelled (one patient in the
standard oxygen group) and withdrawal of consent
(one patient in the standard oxygen group) (Fig. 1).
All other randomly allocated patients were included in
the intention-to-treat analysis. Baseline and clinical
characteristics (including logistic EuroScore) are shown in
Table 1. Study end-points are reported in Table 2.
Median (IQR [range]) hospital length of stay was 7 (6–9
[4–30]) and 9 (7–16 [4–120]) days in the high-ﬂow nasal
oxygen group and the standard oxygen group,
respectively, p = 0.012. The geometric mean hospital
length of stay was 29% lower in the high-ﬂow nasal
oxygen group (95%CI: 11–44%), p = 0.004. A sensitivity
analysis removing the single outlying value (120 days)
from the standard oxygen group did not materially alter
the conclusions (Figure 2). The risk of prolonged stay
was 18.7% in the high-ﬂow nasal oxygen group
compared with 38.6% in the standard oxygen group
(RR 0.49, 95%CI: 0.24–0.97), p = 0.0343. There was no
difference in ICU length of stay (p = 0.949) with the med-
ian (IQR [range]) being 1 (1–2 [1–15]) and 1 (1–2
[1–23]) in the high-ﬂow nasal oxygen group and standard
oxygen group, respectively. Patients in the high-ﬂow
nasal oxygen group had fewer ICU re-admissions (1/49
vs. 7/45; p = 0.026). There was one death in each group.
Less than half of the patients enrolled performed a
postoperative 6MWT. The mean (SD) distance was 207.3
(98.9) m in the high-ﬂow nasal oxygen group compared
with 186.1 (114.9) m in the standard oxygen group;
mean difference was 21.3 m (95%CI: 44.0 to 86.6),
p = 0.510. Postoperative pulmonary function tests were
performed in two-thirds of the patients. There was no
signiﬁcant difference between the two groups in terms
of FEV1 and FVC. The number of patients requiring
escalation of respiratory support (unplanned CPAP,
non-invasive or invasive ventilation) was three (6.1%) in
the high-ﬂow nasal oxygen group compared with six
(13.3%) in the standard oxygen group (p = 0.190). One
patient (in the standard oxygen group) required a tra-
cheostomy to aid weaning from mechanical ventilation.
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Four patients in the standard oxygen group crossed
over and received high-ﬂow nasal oxygen after 24 h
(two patients required high-ﬂow nasal oxygen for 48 h
and the other two for 72 h). There were no signiﬁ-
cant between-group differences in extra-pulmonary
postoperative complications (Table 3). The recovery
proﬁles for each PQRS domain are summarised in
Table 4. The differences in patient-reported outcomes
between the two groups were not statistically signiﬁcant.
Discussion
In this study, we randomly assigned patients undergoing
cardiac surgery and at high risk for postoperative pul-
monary complications to receive either high-ﬂow nasal
• Delayed extubaon (n = 2)
• Withdrew consent (n = 1)
Paents undergoing coronary artery 
bypass graing, valve surgery or both 
were assessed for eligibility (n = 1714)
Excluded (n = 1614)
• Not meeng inclusion criteria (n = 1187)
• Declined to parcipate (n = 69)
• Failed to consent (n = 8)
• Withdrew from study before randomisaon
(n = 1)
• Study team not available (n = 349)
Included in analysis for primary outcome 
(n = 49)
• Delayed extubaon (n = 2)
High-flow nasal oxygen group
(n = 51)
Standard oxygen group
(n = 49)
• Procedure cancelled (n =1)
Included in analysis for primary outcome 
(n = 45)
Allocaon
Randomised (n = 100)
Enrolment
Follow-Up
Analysis
Figure 1 Study ﬂow (CONSORT) chart showing patients allocated to either high-ﬂow nasal oxygen or standard oxygen
therapy.
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oxygen or standard oxygen therapy following tracheal
extubation. This is the ﬁrst randomised controlled trial
examining the effect of prophylactic use of high-ﬂow
nasal oxygen on clinical outcomes in cardiac surgical
patients with signiﬁcant risk factors for peri-operative
pulmonary complications. We demonstrated that high-
ﬂow nasal oxygen use resulted in a statistically signiﬁ-
cant reduction in hospital length of stay and fewer
re-admissions to ICU. There were no signiﬁcant
between-group differences in other secondary outcomes.
Airﬂow limitation strongly predicts increased hospital
stay and in-hospital mortality after cardiac surgery [24].
The beneﬁcial effect of high-ﬂow nasal oxygen after
cardiac surgery and reduction in hospital stay in our
study cohort could potentially be explained by the follow-
ing mechanisms: washout of nasopharyngeal dead space;
reduced work of breathing; improved respiratory
mechanics; and generation of low-level PEEP [25–27].
The warmed and humidiﬁed oxygen facilitates optimum
function of the airway mucosa and mucociliary clearance,
and inhibits bronchomotor response, thus preventing
bronchospasm and increases in airway resistance
[28, 29]. It has been shown that high-ﬂow nasal
oxygen reduces dead space ventilation in a ﬂow- and
time-dependent manner, leading to a reduction in
rebreathing, more effective alveolar ventilation and
Table 1 Baseline characteristics of patients receiving high-ﬂow nasal oxygen or standard oxygen therapy. Values are mean
(SD), number (proportion) or median (IQR [range]).
High-ﬂow nasal oxygen group Standard oxygen group
n = 49 n = 45
Age; y 67.3 (9.3) 69.1 (11.1)
Sex; female 19 (38.8%) 17 (37.8%)
Comorbiditiesa
COPDb 14 (28.6%) 15 (33.3%)
Asthmab 18 (36.7%) 19 (42.2%)
Smoker 10 (20.4%) 10 (22.2%)
BMI ≥ 35 kg.m2 13 (26.5%) 12 (26.7%)
Recent LRTIc 0 0
BMI; kg.m2 32 (5.5) 30.2 (6.6)
Pre-operative Hb; g.l1 137 (129–145 [111–156]) 131 (127–141 [85–166])
Pre-operative creatinine; lmol.l1 80 (71–90 [52–141]) 83 (74–96 [38–180])
Logistic EUROScored 4 (3–7 [1–30]) 4 (3–10 [1–26])
Six-minute walk test; m 334.4 (283.0–397.1 [108.0–481.0]) 348.2 (275.0–392.5 [130.0–596.0])
FEV1; l 2.3 (1.8–2.7 [0.8–3.8]) 2.0 (1.6–2.4 [1.0–3.9])
FEV1; % of predicted value 87 (72–101 [41–127]) 81 (68–89 [42–147])
FVC; l 3.3 (2.4–3.7 [1.5–5.2]) 3.0 (2.4–3.5 [1.5–5.4])
FVC; % of predicted value 89 (81–107 [49–138]) 92 (77–104 [41–169])
Procedure
CABG 17 (34.7%) 14 (31.1%)
Valve(s) 24 (49.0%) 18 (40.0%)
CABG + Valve(s) 8 (16.3%) 13 (28.9%)
Surgery time; min 197 (176–225 [100–327]) 202 (169–274 [55–470])
BMI, body mass index; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; EuroScore, European
System for Cardiac Operative Risk Evaluation; Hb, haemoglobin; FEV1, forced expiratory volume in one second; FVC, forced vital
capacity.
aMore than one pathology may be present in each patient.
bOnly patients with a formal COPD or asthma diagnosis (as deﬁned by British Thoracic Society and National Institute for Health
and Care Excellence) on inhaled therapy were enrolled [18, 19].
cLRTI was deﬁned according to National Institute for Health and Care Excellence as an acute illness, usually with cough as the main
symptom, and with at least one other lower respiratory tract symptom (such as fever, sputum production, breathlessness, wheeze
or chest discomfort or pain) and no alternative explanation [20].
dLogistic EUROSCORE is a risk model which allows prediction of mortality after cardiac surgery. It includes 17 factors (patient-,
cardiac- and operation related) and uses logistic regression to calculate mortality risk.
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decreased work of breathing [26]. Furthermore, high-ﬂow
nasal oxygen provides PEEP of 3–5 cmH2O at ﬂows
of 30–50 l.min1 which could potentially reduce
postoperative atelectasis [15]. Prevention of postoperative
hypoxaemia and hypercapnia, together with improved
pulmonary mechanics, not only reduces pulmonary
morbidity but may also improve cardiac function by
reducing myocardial oxygen demand and the adverse
effects of impaired gas exchange on pulmonary vasculature.
These mechanisms could explain the beneﬁcial effect of
prophylactic high-ﬂow nasal oxygen use in the immediate
postoperative period. We would, therefore, expect an
improvement in postoperative pulmonary function and
6MWT which we were unable to demonstrate. A possible
explanation for these results could be that the study was
not powered to compare those secondary outcomes, or
that patients had limited physiological reserve due to
chronic lung disease (COPD, asthma), recent sternotomy
and major surgery.
In the non-cardiac surgery setting, high-ﬂow nasal
oxygen is increasingly being used as a ﬁrst-line therapy
in acute respiratory failure. This strategy is supported by
data from well-designed and adequately powered trials
showing that high-ﬂow nasal oxygen application reduces
tracheal re-intubation rate in low-risk patients [30] when
compared with conventional oxygen therapy, confers
survival beneﬁt [31] and results in a lower tracheal
re-intubation rate [32] in patients with, or at risk of,
non-hypercapnic hypoxaemic respiratory failure.
However, a recent systematic review of 11 randomised
trials (n = 1972) examining the safety and efﬁcacy of
Table 2 Study end-points for patients randomly allocated to either the high-ﬂow nasal oxygen group or standard oxygen
group. Values are median (IQR [range]) or number (proportion).
High-ﬂow nasal oxygen group Standard oxygen group
p valuen = 49 n = 45
Total length of stay; days 7 (6–9 [4–30]) 9 (7–16 [4–120]) 0.012
ICU length of stay; days 1 (1–2 [1–15]) 1 (1–2 [1–23]) 0.949
Re-admission to ICU 1 (2.0%) 7 (15.6%) 0.026
Six-minute walk test; m 214 (116–280 [40–380]) 165 (98–251 [60–510]) 0.330
Lung function
FVC; l 1.9 (1.6–2.3 [0.8–3.8]) 1.9 (1.5–2.3 [0.9–3.5]) 0.480
FVC; % of predicted value 57 (45–66 [31–102]) 57 (47–69 [34–123]) 0.990
FEV1; l 1.5 (1.1–1.7 [0.7–2.5]) 1.2 (1.1–1.5 [0.5–2.7]) 0.180
FEV1; % of predicted value 54 (42–64 [29–81]) 53 (39–65 [18–83]) 0.690
ICU, intensive care unit; FEV1, forced expiratory volume in one second; FVC, forced vital capacity.
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Figure 2 Box plot showing hospital length of stay in
cardiac surgical patients allocated to either high-ﬂow nasal
oxygen (HFNO) or standard oxygen therapy. The horizontal
line is the median value, the box is the interquartile range
and the whiskers extend out to the adjacent values.
Outliers are plotted individually as open circles.
Table 3 Extra-pulmonary complications in patients allo-
cated to either high-ﬂow nasal oxygen or standard
oxygen therapy.
High-ﬂow
nasal
oxygen
group
Standard
oxygen
group
p valuen = 51 n = 49
Return to operating
theatre
2 3 0.628
Atrial ﬁbrillation 1 5 0.101
Pacemaker insertion 1 4 0.190
Renal replacement
therapy
3 3 1.000
Sternal wound
infection
0 1 0.479
Delirium 2 4 0.421
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high-ﬂow nasal oxygen in general ICU patients requiring
respiratory support found insufﬁcient evidence to
determine superiority of high-ﬂow nasal oxygen in the
ICU setting [33]. In a pragmatic randomised controlled
trial, Parke et al. demonstrated that high-ﬂow nasal
oxygen did not improve outcomes as assessed by oxygen
saturation to fraction of inspired oxygen (SpO2/FIO2)
ratio after cardiac surgery, but did reduce the
requirement for escalation of respiratory support [34]. In
a recent randomised controlled trial, Corley et al.
compared prophylactic tracheal extubation followed by
high-ﬂow nasal oxygen for 8 h with standard care
post-cardiac surgery in obese patients (BMI ≥ 30 kg.m2)
[35]. Primary outcome was atelectasis on postoperative
chest radiograph. Prophylactic tracheal extubation
followed by high-ﬂow nasal oxygen did not lead to
improvements in respiratory function or a statistically
signiﬁcant difference in ICU stay. The limited high-ﬂow
nasal oxygen exposure time (8 h) in the Corley trial and
use of surrogate (SpO2/FIO2 ratio and atelectasis score)
markers, rather than patient-oriented primary outcomes
(which would have required a much larger sample size),
were the main limitations of these studies. Furthermore,
reporting ‘non-validated’ surrogate primary outcomes is
more likely to result in overestimation of treatment effect
and uncertainty in predicting treatment beneﬁt [36].
We selected hospital stay as the primary outcome
because it is more relevant to patients and healthcare
providers than physiological parameters such as
oxygenation or haemodynamic data. Length of stay
integrates postoperative pulmonary and extra-pulmonary
complications, and speed of postoperative recovery. It is,
therefore, a non-mortality patient-centred outcome
which reﬂects quality and value-based healthcare delivery
[37, 38].
A recent meta-analysis which included the
aforementioned two randomised trials only, examined
the efﬁcacy and safety of high-ﬂow nasal oxygen after
cardiac surgery compared with conventional oxygen
therapy and found that post-extubation application of
high-ﬂow nasal oxygen was associated with a signiﬁcant
reduction in escalation of respiratory support (RR, 0.61;
95%CI, 0.46–0.82; z = 3.32, p < 0.001) [39]. However,
due to the small number of studies analysed, the
methods utilised to detect publication bias were
underpowered. In addition, the deﬁnitions, strategies and
criteria for escalation of respiratory support in the studies
included in the meta-analysis were non-speciﬁc, making
the validity of the results questionable. The differences in
escalation of respiratory support (unplanned CPAP,
non-invasive or invasive ventilation) between the
high-ﬂow nasal oxygen group and the standard oxygen
group in our study cohort were non-signiﬁcant.
In a large (n = 830) ‘non-inferiority’ multi-centre
randomised trial, high-ﬂow nasal oxygen was compared
with BiPAP in patients with, or at risk of, respiratory failure
after cardiothoracic surgery [40]. The primary outcome in
this study was treatment failure, which was deﬁned as a
composite of tracheal re-intubation, switch to the other
study therapy or early discontinuation of the assigned
Table 4 Patient-reported outcomes from patients randomly allocated to high-ﬂow nasal oxygen or standard oxygen
therapy. Values are proportion recovery from baseline.
Domain Time High-ﬂow nasal oxygen (%) Standard oxygen (%) p valuee p valuef
Nociceptivea 5 days 40.5 35.9 0.677 0.535
1 month 40.5 37.9 0.830
Emotionalb 5 days 78.4 71.8 0.508 0.773
1 month 65.8 75.9 0.372
ADLc 5 days 86.5 83.8 0.744 0.576
1 month 89.5 86.2 0.683
Cognitive 5 days 65.7 69.2 0.772 0.483
1 month 72.2 87.5 0.227
Satisfactiond 5 days 97.4 97.4 1.000 0.239
1 month 87.8 96.6 0.198
aNociception, pain and nausea.
bEmotional, anxiety and depression.
cADL, activities of daily living (eat, walk, stand, dress).
dSatisfaction, overall satisfaction with anaesthetic care, reported as satisﬁed or very satisﬁed.
ep value for comparison at each visit.
fp value for comparison over both follow-up visits.
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therapy, and the authors concluded that high-ﬂow nasal
oxygen was not inferior to BiPAP. The control group in
this study does not necessarily represent the standard of
care or best practice because there are no robust data
indicating that BiPAP improves outcomes in the cardiac
surgery setting. In addition, by using a composite primary
outcome, the effect may be small for important individual
components (e.g. tracheal re-intubation rate) and large
for less important clinical components (e.g. crossover to
another treatment group), limiting the generalisability of
the results [41]. A recent post-hoc analysis in the subset
of obese (BMI > 30 kg.m2) patients from the same
randomised controlled trial showed that continuous
application of high-ﬂow nasal oxygen compared with
intermittent BiPAP in patients with or without respiratory
failure did not lead to a higher rate of treatment failure
[42]. The use of BiPAP was associated with improved
oxygenation indices; however this did not translate into
improved clinical outcomes.
None of the high-ﬂow nasal oxygen studies
previously undertaken in the cardiac surgery setting were
powered to detect differences in clinically important
primary outcomes such as mortality or length of stay. No
study exclusively investigated the effect of high-ﬂow nasal
oxygen on outcomes in patients at signiﬁcantly higher
risk of postoperative pulmonary dysfunction, such as
patients with pre-existing pulmonary disease. Two studies
focused on obese patients who are at higher risk of
postoperative pulmonary complications, but methodological
ﬂaws relating to their ‘non-inferiority’ design and post-hoc
analysis diminish the validity of their results [40, 42].
Our trial has several limitations. Firstly, there is
potential bias due to a lack of blinding of the patients
and healthcare providers in the immediate postoperative
period due to the obvious differences between the study
interventions. Secondly, our study was underpowered for
some of the secondary outcomes, for example, 6MWT
and patient-reported outcomes, and the composite of
postoperative complications. Although we did not
discern signiﬁcant between-group differences in patient-
reported outcomes, we highlight the importance of
reporting recovery proﬁles as they reﬂect value-based
care and provide potentially useful information in order
to adequately power future studies. Thirdly, the single
centre status of our study and potentially associated
large intervention effect may not be directly transferable
to other settings [43].
In conclusion, when compared with standard care,
prophylactic postoperative use of high-ﬂow nasal
oxygen in cardiac surgical patients at high risk for
postoperative respiratory complications reduced hospi-
tal length of stay and re-admissions to ICU. This has
implications for reduced healthcare costs and
potentially morbidity. We recommend routine use of
high-ﬂow nasal oxygen after tracheal extubation in this
cohort of patients and further testing of our hypothesis
in large multi-centre randomised trials.
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